Britain and America have concluded a key bilateral deal that will maintain zero import taxes on UK pharmaceutical products entering the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the public health system. This pledge guarantees that import taxes on these key goods will stay at nothing for a timeframe of 36 months.
This deal comes after previous statements to dramatically increase import taxes on branded pharmaceutical products, with increases discussed up to double the cost.
"This agreement between the Britain reinforces the global environment for new treatments and brings long-overdue fairness to U.S.–U.K. medicine commerce," a release said.
Commercial Impact
Drugs represent one of the the United Kingdom's most significant goods shipped to the United States, which is by far the biggest buyer for leading UK drugmakers.
Export figures indicate that in the year prior to the third quarter, the UK shipped drugs valued at billions to the US. This figure accounted for a significant portion of all goods exports in that span.
"This agreement secures employment, boosts capital expenditure and paves the way for the UK to establish itself as a worldwide center for medical research," a minister stated.
Specific NHS Changes
The deal involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Increased NHS Spending: There is a goal to raise total NHS spending on drugs from 0.3% of GDP to 0.6% over the coming ten years.
- Payback Limit: The sum manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, repayments exceeded 20%.
Industry Background
This agreement comes amid a protracted row between the pharmaceutical industry and the UK government over medicine costs and regulatory access.
This friction were heightened by arguments that US patients were charged a premium for the same drugs than people in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while multi-billion-dollar expansions have been directed toward American operations.
A senior figure publicly accepted that the NHS had to invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the last ten years.
